Jordi Remon/X
Mar 26, 2025, 17:42
Jordi Remon: We had efficacy data on ADCs after osimertinib and PD in EGFR-mutant NSCLC
Jordi Remon, Cancer Specialist at CIOCC Barcelona, shared on X:
“We had efficacy data ADCs after osi-PD in EGFRm NSCLC. Today good mPFS (9.5-11.7) with Osi+DatopotamAb Dxd after osi-PD. Data looks promising than chemo+Amiv. Better protection maintaining osi? Biomarker for dato? Toxicity is imp. Future trial: osi-DATOD vs Ami-CT?”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 24, 2025, 06:31
Jun 24, 2025, 06:02
Jun 24, 2025, 05:47
Jun 24, 2025, 05:20